Revenue $12.59B, up 13.0% on a year earlier. Core Laboratory Diagnostics sales $1.42B, up 4.4%. Diabetes Care sales $2.19B, up 10.4%. Diluted EPS $0.53 against $1.01.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $12.59B | $11.16B | $11.14B | +13.0% |
| Operating income | $1.69B | $1.34B | $2.05B | -17.5% |
| Net income | $928.00M | $1.08B | $1.78B | -47.8% |
| Diluted EPS | $0.53 | $0.61 | $1.01 | |
| Operating cash flow | $2.49B | $1.31B | $2.05B | +21.5% |
| Capital expenditures | -$497.00M | -$399.00M | -$502.00M | |
| Free cash flow | $1.99B | $916.00M | $1.54B | +28.9% |
| Dividend per share | $0.63 | $0.63 | $0.59 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Core Laboratory Diagnostics sales | $1.42B | $1.36B | +4.4% |
| Diabetes Care sales | $2.19B | $1.98B | +10.4% |
| Diagnostics sales | $3.09B | $2.17B | +42.3% |
| Established Pharmaceuticals sales | $1.50B | $1.38B | +8.4% |
| International sales | $7.38B | $6.87B | +7.4% |
| Nutrition sales | $2.14B | $2.21B | -3.1% |
| Organic sales growth | 4.8% | 6.9% | |
| U.S. sales | $5.22B | $4.28B | +22.0% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Abbott Laboratories (ABT) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/ABT/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
